866-997-4948(US-Canada Toll Free)

Oral Mucositis - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Mar 2014

Category :

Oncology

No. of Pages : 104 Pages

Oral Mucositis - Pipeline Review, H1 2014

Summary

Global Markets Directs, Oral Mucositis - Pipeline Review, H1 2014, provides an overview of the Oral Mucositiss therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Oral Mucositis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Oral Mucositis and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Oral Mucositis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Oral Mucositis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Oral Mucositis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Oral Mucositis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Oral Mucositis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Oral Mucositis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Oral Mucositis Overview 9
Therapeutics Development 10
Pipeline Products for Oral Mucositis Overview 10
Pipeline Products for Oral Mucositis Comparative Analysis 11
Oral Mucositis Therapeutics under Development by Companies 12
Oral Mucositis Therapeutics under Investigation by Universities/Institutes 15
Oral Mucositis Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Oral Mucositis Products under Development by Companies 20
Oral Mucositis Products under Investigation by Universities/Institutes 21
Oral Mucositis Companies Involved in Therapeutics Development 22
Daewoong Pharmaceutical Co., Ltd. 22
Soligenix, Inc. 23
BioAlliance Pharma SA 24
Sucampo Pharmaceuticals, Inc. 25
ActogeniX NV 26
Alder Biopharmaceuticals Inc. 27
Promedior, Inc. 28
ProCertus BioPharm Inc. 29
GliaMed, Inc. 30
Avaxia Biologics, Inc. 31
Cellceutix Corporation 32
Vicus Therapeutics, LLC 33
Nephrx Corporation 34
Laila Pharmaceuticals Pvt. Ltd. 35
Applied Protein Sciences, LLC 36
Oral Mucositis Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Target 39
Assessment by Mechanism of Action 42
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 49
nepidermin - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Lactobacillus CD2 Lozenges - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
sucralfate - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
clonidine hydrochloride ER - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
clazakizumab - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
SGX-942 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
LP-004-09 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
methionine - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Quercetin - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
selenium sulfide - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
AG-013 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
cobiprostone - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
GC-4403 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
GM-1485 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
brilacidin - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
PRM-151 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
NX-002 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Hybrid Adenoretroviral Vectors - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Regenasyn - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
GC-4419 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
AP-002 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
AP-001 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
OralX - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
(captopril + teprenone) - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Anti-TNF Antibody For Oral Mucositis - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Oral Mucositis Recent Pipeline Updates 80
Oral Mucositis Dormant Projects 94
Oral Mucositis Discontinued Products 95
Oral Mucositis Product Development Milestones 96
Featured News & Press Releases 96
Feb 18, 2014: Access Pharmaceuticals Announces Publication Of MuGard Clinical Data In Cancer Journal 96
Jan 23, 2014: FDA Grants Validive with a Fast Track Designation for the Prevention and Treatment of Oral Mucositis Induced by Anticancer Treatments 97
Dec 20, 2013: Cellceutix Files Orphan Drug Designation Application for Brilacidin for Oral Mucositis With US FDA 97
Dec 05, 2013: Soligenix Announces Initiation of a Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 98
Sep 30, 2013: BioAlliance Pharma : First Meeting of the International Advisory Board on Oral Mucositis and Development of Validive 98
Jun 10, 2013: BioAlliance Pharma Initiates Phase II Clinical Trial With Validive In US 99
Jun 03, 2013: Soligenix's SGX942 Receives FDA Fast Track Designation For Treatment Of Oral Mucositis In Patients With Head And Neck Cancer 99
Mar 27, 2013: Soligenix Receives IND Clearance From FDA To Initiate Clinical Program To Evaluate SGX942 For Treatment Of Oral Mucositis 100
Feb 14, 2013: BioAlliance Pharma Announces Forthcoming Extension Of Its Phase II Clinical Trial With Validive In US 101
Sep 19, 2012: PolyMedix Receives Grant From National Cancer Institute To Study Brilacidin For Oral Mucositis 101
Appendix 103
Methodology 103
Coverage 103
Secondary Research 103
Primary Research 103
Expert Panel Validation 103
Contact Us 104
Disclaimer 104

List of Table

List of Tables
Number of Products under Development for Oral Mucositis, H1 2014 10
Number of Products under Development for Oral Mucositis Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 13
Number of Products under Development by Companies, H1 2014 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2014 16
Comparative Analysis by Late Stage Development, H1 2014 17
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Early Stage Development, H1 2014 19
Products under Development by Companies, H1 2014 20
Products under Investigation by Universities/Institutes, H1 2014 21
Oral Mucositis Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2014 22
Oral Mucositis Pipeline by Soligenix, Inc., H1 2014 23
Oral Mucositis Pipeline by BioAlliance Pharma SA, H1 2014 24
Oral Mucositis Pipeline by Sucampo Pharmaceuticals, Inc., H1 2014 25
Oral Mucositis Pipeline by ActogeniX NV, H1 2014 26
Oral Mucositis Pipeline by Alder Biopharmaceuticals Inc., H1 2014 27
Oral Mucositis Pipeline by Promedior, Inc., H1 2014 28
Oral Mucositis Pipeline by ProCertus BioPharm Inc., H1 2014 29
Oral Mucositis Pipeline by GliaMed, Inc., H1 2014 30
Oral Mucositis Pipeline by Avaxia Biologics, Inc., H1 2014 31
Oral Mucositis Pipeline by Cellceutix Corporation, H1 2014 32
Oral Mucositis Pipeline by Vicus Therapeutics, LLC, H1 2014 33
Oral Mucositis Pipeline by Nephrx Corporation, H1 2014 34
Oral Mucositis Pipeline by Laila Pharmaceuticals Pvt. Ltd., H1 2014 35
Oral Mucositis Pipeline by Applied Protein Sciences, LLC, H1 2014 36
Assessment by Monotherapy Products, H1 2014 37
Assessment by Combination Products, H1 2014 38
Number of Products by Stage and Target, H1 2014 41
Number of Products by Stage and Mechanism of Action, H1 2014 44
Number of Products by Stage and Route of Administration, H1 2014 46
Number of Products by Stage and Molecule Type, H1 2014 48
Oral Mucositis Therapeutics Recent Pipeline Updates, H1 2014 80
Oral Mucositis Dormant Projects, H1 2014 94
Oral Mucositis Discontinued Products, H1 2014 95

List of Chart

List of Figures
Number of Products under Development for Oral Mucositis, H1 2014 10
Number of Products under Development for Oral Mucositis Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 15
Comparative Analysis by Late Stage Development, H1 2014 17
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Early Stage Products, H1 2014 19
Assessment by Monotherapy Products, H1 2014 37
Number of Products by Top 10 Target, H1 2014 39
Number of Products by Stage and Top 10 Target, H1 2014 40
Number of Products by Top 10 Mechanism of Action, H1 2014 42
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 43
Number of Products by Top 10 Route of Administration, H1 2014 45
Number of Products by Stage and Top 10 Route of Administration, H1 2014 46
Number of Products by Top 10 Molecule Type, H1 2014 47
Number of Products by Stage and Top 10 Molecule Type, H1 2014 48

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *